A lead-212 alpha therapy for neuroendocrine tumors heads to FDA end-of-Phase 2 talks in early 2027

Perspective Therapeutics' lead-212 alpha therapy for neuroendocrine tumors is moving toward a late-stage trial: the Seattle company said on November 9, 2026, that it aims to meet the FDA about Phase 3 in early 2027. The quarterly update gave no efficacy figures, but trial investigators reported tumor responses at a conference days earlier.

Key points

• Perspective says it aims to hold its end-of-Phase 2 FDA meeting for bamzireotide navoxetan (VMT-α-NET), its neuroendocrine tumor drug, in the first quarter of 2027.
• The fourth dose-finding cohort for neuroendocrine tumors closed on October 30, 2026, with 20 patients, while a meningioma cohort stays open with two patients treated.
• At the NANETS symposium in November, investigators reported objective responses in 32.6% of patients at the 5.0 mCi dose and 50% at 6.0 mCi, with no grade 4 or 5 adverse events (Cancer Therapy Advisor).
• The FDA gave a second drug, PSV359, Fast Track designation in October 2026 for adults with advanced FAP-positive solitary fibrous tumors, the company says.
• Perspective reported about $202 million in cash and short-term investments on September 30, 2026, which it expects to last into 2028, after a third-quarter net loss of $32.4 million.

What is a lead-212 alpha therapy?

It is a radiopharmaceutical: a molecule that seeks out a protein on tumor cells and carries a radioactive atom, here lead-212, that emits alpha particles at close range. Perspective describes its approach as "theranostic", pairing each treatment with an imaging agent that uses the same targeting molecule so doctors can see which tumors it reaches before treating them. Its lead program, bamzireotide navoxetan, targets the SSTR2 receptor found on many neuroendocrine tumors.

The registry entry for the main study, a Phase I/IIa trial that began in September 2023, lists an estimated 300 participants across neuroendocrine tumors, paraganglioma, pheochromocytoma and meningioma (NCT05636618).

What did Perspective report on its lead-212 alpha therapy this quarter?

Mostly progress on timelines rather than new results. The company says updated interim data on bamzireotide were presented at the ESMO Congress and the NANETS symposium this year, and that the findings support what it calls an emerging therapeutic window, but the quarterly update itself repeats no response rates or side-effect counts. Europe granted the drug orphan designation for gastroenteropancreatic neuroendocrine tumors in July 2026, according to the release.

The numbers are in the conference presentation. Thorvardur Halfdanarson of the Mayo Clinic presented cohorts 1 to 3 at NANETS 2026: of 68 treated patients (2 at 2.5 mCi, 46 at 5.0 mCi and 20 at 6.0 mCi), 15 of 46 at 5.0 mCi (32.6%) and 10 of 20 at 6.0 mCi (50%) had an objective response, the overall 18-month progression-free survival estimate was 71.5%, and 29.4% had grade 3 treatment-emergent adverse events, with none at grade 4 or 5 (Cancer Therapy Advisor). The same report notes the study was supported by Perspective and excluded patients who had already received radioligand therapy.

In melanoma, the company says its second drug, lapemelanotide zapixetar (VMT01), showed durable disease control in heavily pre-treated patients in data shown at SITC, the Society for Immunotherapy of Cancer meeting. It has reopened a monotherapy cohort to confirm that signal: 12 patients have been treated in that cohort, and the five treated since it reopened in the third quarter are expected to reach at least 24 weeks of follow-up by mid-2027.

What does Fast Track mean for PSV359?

Fast Track is an FDA process for drugs aimed at serious conditions with an unmet need; it brings more frequent meetings and written feedback from the agency, possible eligibility for accelerated approval and priority review, and the option of submitting an application in sections (FDA). It is not an approval and says nothing on its own about whether a drug works.

PSV359 targets fibroblast activation protein (FAP), a protein found in the supporting tissue of many solid tumors. Perspective says 17 patients had been treated across three dose cohorts by September 30, 2026, with the next clinical update planned for 2027. The trial's registry entry lists pancreatic, gastric, esophageal, colorectal, ovarian and head and neck cancers, sarcoma and mesothelioma among its targets (NCT06710756). Separately, the company signed a clinical trial collaboration and supply agreement with Merck in September 2026 to support a possible test of PSV359 alongside Keytruda (pembrolizumab) in some lung and colorectal cancers.

What does it mean for oncology teams and patients?

Our analysis: for clinicians treating neuroendocrine tumors, the useful date is the first quarter of 2027, when Perspective expects to learn from the FDA what a Phase 3 trial must show; a registrational trial, and any approval, would come after that.

The benchmark it will be measured against is Lutathera (lutetium Lu 177 dotatate), an approved radiolabeled somatostatin analog labelled for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in patients 12 and older (FDA label on DailyMed). Lutathera's approval rests on NETTER-1, a randomized, active-controlled trial (FDA label on DailyMed); bamzireotide's figures so far come from a company-funded, single-arm dose-finding study, so its claims of a best-in-class profile are the company's view, not a finding.

The release also does not say which lung and colorectal cancers the Merck combination would cover, when such a study would start, or what each company contributes.

Readers new to how trial phases work can start with our guide to how clinical trials shape future healthcare, and our roundup on how technology supports clinical trials and research.

Supply is part of the picture for any radiopharmaceutical. Perspective makes lead-212 from a radium-224 generator and says construction of its Chicago metro manufacturing site should finish in early 2027.

Frequently asked questions

What is bamzireotide navoxetan?

Bamzireotide navoxetan (VMT-α-NET) is Perspective Therapeutics' investigational lead-212 alpha therapy for SSTR2-positive neuroendocrine tumors and meningioma, now in a Phase I/IIa trial. It is not approved anywhere.

When will Perspective Therapeutics meet the FDA about Phase 3?

The company says it plans to hold that end-of-Phase 2 FDA meeting in the first quarter of 2027.

What response rates has bamzireotide navoxetan shown?

At NANETS 2026, investigators reported objective responses in 32.6% of patients at 5.0 mCi and 50% at 6.0 mCi, in the two higher-dose cohorts of a single-arm study that treated 68 patients (Cancer Therapy Advisor).

What did the FDA grant PSV359?

Fast Track designation, in October 2026, for adults with locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors, according to the company. Fast Track speeds communication with the FDA; it is not an approval.

How long will Perspective's cash last?

Perspective says its roughly $202 million in cash and short-term investments at September 30, 2026, should fund its planned clinical milestones and operations into 2028.

Sources

• Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results: press release from Perspective Therapeutics via GlobeNewswire, 9 November 2026.
• NCT05636618: the bamzireotide navoxetan Phase I/IIa trial record on ClinicalTrials.gov.
• NCT06710756: the PSV359 Phase I/IIa trial record on ClinicalTrials.gov.
• Fast Track: the FDA's explanation of the designation.
• 212Pb VMT-a-NET Appears Safe, Effective in SSTR2-Expressing NETS: Cancer Therapy Advisor's report of the NANETS 2026 presentation, 7 November 2026.
• Lutathera (lutetium Lu 177 dotatate) prescribing information: the FDA-approved label, on the National Library of Medicine's DailyMed.
• Perspective Therapeutics: the company's website.